Three mRNA HIV Vaccines have been trialed

Three mRNA HIV Vaccines have been trialed ...

Three preventive HIV vaccinations will be tested in a Phase I clinical experiment with mRNA technology.

HVTN 302 clinical trial

Three experimental vaccinations will be tested: BG505 MD39.3 mRNA, BG505 MD39.3 gp151 mRNA, and BG505 MD39.3 gp151 CD4KO mRNA in 108 healthy participants aged 1855 years. These experimental vaccinations have been developed by Moderna in partnership with the National Institute of Allergy and Infectious Diseases (NIAID).

What are the benefits of mRNA vaccinations?

The messenger ribonucleic acid (mRNA) which encodes a specific viral protein leads to endogenous production of the protein in the recipient''s cells. This results in an immune response, ensuring that the body receives the virus.

Instead of encoding the SARS-CoV-2 spike protein, as in COVID-19 mRNA vaccines, the three vaccinations in HVTN 302 encode trimers stabilized proteins found on the surface of HIV. These proteins are vital for HIV to enter human cells and cause infection. Each of the three mRNA sequences, developed through Steichen et al, encode a slightly different form of the protein.

HVTN 302 trial structure

The investigators for the trials are Dr. Jesse Clark, an associate professor-in-residence in the department of medicine at the University of California Los Angeles, and Dr. Sharon Riddler, the associate chief of clinical research at the University of Pittsburgh. Eleven sites across the United States will be recruiting participants for the trial, which will be randomly allocated to receive three doses of one of the mRNA vaccines. The study, which is expected to begin by July 2023, is titled:

Group A Three groups of 18 participants will receive an intramuscular injection (100 mg) of the assigned vaccination at baseline, month two, and month six.

Group B will be dragged after an initial safety criteria assessment.

Group B At baseline, three groups of 18 participants will receive an intramuscular injection (250 mg) of the assigned vaccination, both at the month two and the month six.

The primary concept is that the BG505 MD39.3 soluble and membrane-bound trimer mRNA vaccinations will be safe and well-tolerated among HIV-infected individuals and will elicit autologous neutralizing antibodies, according to ClinicalTrials.gov.

Difficulties in developing a HIV vaccine

A preventive or therapeutic vaccine for HIV is yet to exist, despite several decades of research. Note that this is not because of the lack of research; HIV is an enormously complex disease that is very effective at mutating. In the pre-clinical development of a medication or preventive vaccine, animal trials are necessary to determine the safety and effectiveness of the investigational medicine (IMP). A virus that mutes often and rapidly is difficult to model, thus making this key step in the development of IMP particularly difficult. If we cannot test

Humans infected with HIV do not have an immune system. Although there are some exceptions, immunization is usually to mimic a natural immune response. It must, therefore, be aware that this is not the case.

Is mRNA technology a solution?

The first mRNA vaccine for emergency use in humans was introduced in 2020. However, decades of research preceded this crucial moment for the mRNA field and the pandemic response.

The HVTN 302 release comes as a result of Modernas'' announcement that it administered its first patient with a mRNA HIV vaccine mRNA-1574 on Monday. The Phase I study will examine the vaccinations'' safety and immunogenicity in 100 HIV-negative individuals aged 55 years.

In January, the non-profit organization International AIDS Vaccine Initiative (IAVI) renewed partnership with Moderna launched a Phase I trial, IAVI G002. This study is examining whether sequential administration of HIV immunogens delivered using mRNA technology can induce B-cell responses, directing their maturation towards broad neutralizing antibody (bnAb) development.

There are no doubts about whether mRNA technology will be the long-distance solution to HIV vaccination development challenges, but it''s clear that both academia and the industry are invested in discovering the truth.

You may also like: